- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study2020 | First Faculty of Medicine
- Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review2017 | First Faculty of Medicine
- Early high efficacy mulitple sclerosis treatment: therapeutic success despite safety barriers2023 | First Faculty of Medicine
- Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Ocrelizumab since the first multiple sclerosis attack - a milestone in reimbursement criteria2022 | First Faculty of Medicine
- The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 20212023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Multiple sclerosis patient suitable for the treatment with ofatumumab2022 | Faculty of Medicine in Hradec Králové
- Měnící se paradigma v oblasti roztroušené sklerózy v imunopatogenezi a v terapii2022 | First Faculty of Medicine
- Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis2021 | First Faculty of Medicine
- Understanding the positive benefit: risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program2017 | First Faculty of Medicine, Second Faculty of Medicine